Abstract
Hepatotoxicity has been noted by several investigators during parenteral use of clindamycin, and some have reported that drug half-life is prolonged in the presence of liver disease. We administered 300 mg of clindamycin intravenously at 12-h intervals for 2 days to patients with acute and chronic hepatitis, cirrhosis, and controls to determine whether clindamycin will exacerbate preexisting hepatic dysfunction or whether drug excretion will be delayed in patients with liver disease as compared with controls. Exacerbation of hepatotoxicity was not found in this study. There was a small, but significant, delay in drug elimination between cirrhotics and controls, even after the first dose of clindamycin (P < 0.05); however, half-lives in all categories were in the range usually considered normal. We conclude that clindamycin can be used in liver disease in some circumstances, if proper precautions are exercised.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Brandl R., Arkenau C., Simon C., Malerczyk V., Eidelloth G. Zur Pharmakokinetik von Clindamycin bei gestörter Leber- und Nierenfunktion. Dtsch Med Wochenschr. 1972 Jul 14;97(28):1057–1059. doi: 10.1055/s-0028-1107497. [DOI] [PubMed] [Google Scholar]
- DeHaan R. M., Metzler C. M., Schellenberg D., Vandenbosch W. D. Pharmacokinetic studies of clindamycin phosphate. J Clin Pharmacol. 1973 May-Jun;13(5):190–209. doi: 10.1002/j.1552-4604.1973.tb00208.x. [DOI] [PubMed] [Google Scholar]
- Elmore M., Rissing J. P., Rink L., Brooks G. F. Clindamycin-associated hepatotoxicity. Am J Med. 1974 Oct;57(4):627–630. doi: 10.1016/0002-9343(74)90015-1. [DOI] [PubMed] [Google Scholar]
- Fass R. J., Saslaw S. Clindamycin: clinical and laboratory evaluation of parenteral therapy. Am J Med Sci. 1972 May;263(5):368–382. [PubMed] [Google Scholar]
- Fass R. J., Scholand J. F., Hodges G. R., Saslaw S. Clindamycin in the treatment of serious anaerobic infections. Ann Intern Med. 1973 Jun;78(6):853–859. doi: 10.7326/0003-4819-78-6-853. [DOI] [PubMed] [Google Scholar]
- Sun F. F., Hsi R. S. Metabolism of clindamycin. I. Absorption and excretion of clindamycin in rat and dog. J Pharm Sci. 1973 Aug;62(8):1265–1269. doi: 10.1002/jps.2600620806. [DOI] [PubMed] [Google Scholar]
- Williams D. N., Crossley K., Hoffman C., Sabath L. D. Parenteral clindamycin phosphate: pharmacology with normal and abnormal liver function and effect on nasal staphylococci. Antimicrob Agents Chemother. 1975 Feb;7(2):153–158. doi: 10.1128/aac.7.2.153. [DOI] [PMC free article] [PubMed] [Google Scholar]